Inhalopédia | Inhalers

Class
- Inhaled corticosteroid (ICS)
Active ingredient
- Ciclesonide
Device
- Metered-dose inhaler
Inhalers techniques and maintenance
Age
- 6 +
Typical use
- Asthma
  Initial controller
Asthma management principles
- COPD (off-label)
  in addition to a dual bronchodilation (LAMA/LABA) when exacerbating
COPD management principles
Marketed strength
- 100 mcg
- 200 mcg
Number of doses
- 120 doses
Dose indicator
- No
Usual adult dosage
- Low | 200 mcg – 1 inh QD
  Medium | 200 mcg – 2 inh QD
  High | 200 mcg – 2 inh BID
  Maximum daily dose: 800 mcg
ICS dosing
Usual pediatric dosage
- 1-11 years
  Low | 100 mcg – 1 inh QD
  Medium | 200 mcg – 1 inh QD
  
  12-17 years
  See adult dosage
ICS dosing
Required inspiratory flow
- < 30 L/min
  Zero internal resistance (R0)
Inspiratory flows
Public coverage
- All provinces | Open/Regular Benefit
Advantages
- Once daily dosing (at low or medium doses)
- Less local side effects
- Suitable for low inspiratory flows
- No synchronism required with a spacer
- Less growth reduction in children
Disadvantages
- Cumbersome with a spacer
- Impossible to know when empty
- Round mouthpiece may be difficult to insert in a spacer
- Contain greenhouse gases
Side Effects

Product monograph

Download

Alvesco®